Carmustine or BCNU is a mustard gas-related α-chloro-nitrosourea compound used as an alkylating agent in chemotherapy. It is used in the treatment of several types of brain cancer (including glioma, glioblastoma multiforme, medulloblastoma and astrocytoma), multiple myeloma and lymphoma (Hodgkin's and non-Hodgkin). Carmustine for injection is marketed under the name BiCNU by Bristol-Myers Squibb.
Bone marrow may take 6 weeks to recover function following treatment with carmustine. Weekly monitoring of platelet and white blood cell counts are recommended as a basis for patient-specific adjustments to dosage regimens. Bone marrow and pulmonary toxicities are a function of lifetime cumulative dose.
Eisai Inc. Divests U.S. Rights for GLIADEL[R] Wafer Polifeprosan 20 with Carmustine Implant to Arbor Pharmaceuticals
Jan 02, 2013; By a News Reporter-Staff News Editor at Biotech Week -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd.,...